Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 904

1.

Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).

Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, Fu X, Gao S, Hu J, Huang Y, Jiang G, Jiao W, Li S, Li G, Li H, Li H, Li X, Liang N, Liu D, Liu H, Liu J, Liu L, Liu Y, Luo Q, Ma H, Mao W, Peng Z, Qiao G, Shao G, Tan L, Tan Q, Wang Q, Wang C, Wu Q, Xu S, Xu S, Xu L, Yang Y, Yu F, Zhang B, Zhang L, Zhao B, Zhi X, Brunelli A, Petersen RH, Liu CC, Ricciuti B, Metro G, Tuzi A, Suter MB, Evison M, Seki N, Sasada S, Izumo T, Cho WC, He J; written on behalf of National Clinical Research Center for Respiratory Disease; Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare; Chinese Alliance Against Lung Cancer; AME Thoracic Surgery Collaborative Group.

Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Review. No abstract available.

2.

Prevalence and phylogenetic analysis of Cryptosporidium infections in Yezo sika deer (Cervus nippon yesoensis) in the Tokachi sub-prefecture of Hokkaido, Japan.

Shirozu T, Soga A, Morishita YK, Seki N, Ko-Ketsu M, Fukumoto S.

Parasitol Int. 2020 Jan 21;76:102064. doi: 10.1016/j.parint.2020.102064. [Epub ahead of print]

PMID:
31978598
3.

Replisome genes regulation by antitumor miR-101-5p in clear cell renal cell carcinoma.

Yamada Y, Nohata N, Uchida A, Kato M, Arai T, Moriya S, Mizuno K, Kojima S, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Cancer Sci. 2020 Jan 23. doi: 10.1111/cas.14327. [Epub ahead of print]

4.

Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Anticancer Drugs. 2020 Mar;31(3):298-303. doi: 10.1097/CAD.0000000000000884.

PMID:
31913197
5.

Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Anticancer Res. 2020 Jan;40(1):335-339. doi: 10.21873/anticanres.13957.

PMID:
31892584
6.

Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis.

Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, Takeuchi T.

Arthritis Res Ther. 2019 Dec 30;21(1):304. doi: 10.1186/s13075-019-2068-7.

7.

Regulation of Oncogenic Targets by miR-99a-3p (Passenger Strand of miR-99a-Duplex) in Head and Neck Squamous Cell Carcinoma.

Okada R, Koshizuka K, Yamada Y, Moriya S, Kikkawa N, Kinoshita T, Hanazawa T, Seki N.

Cells. 2019 Nov 28;8(12). pii: E1535. doi: 10.3390/cells8121535.

8.

Neoadjuvant chemotherapy of capecitabine + epirubicin + cyclophosphamide combination therapy ( 'CEX' therapy) for HER-2 negative breast cancer, as retrospective study in our institute.

Yokoyama T, Makino H, Seki N, Ueda J, Hosone M, Katayama H, Takei H, Yoshida H.

J Nippon Med Sch. 2019 Nov 28. doi: 10.1272/jnms.JNMS.2020_87-204. [Epub ahead of print]

9.

Importance and Difficulty of Differentiating BMA-induced AFF Prodromal Symptoms from Hormonal Therapy-related Femoral Pain.

Ota S, Tokizaki T, Sugimoto M, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Kawano H, Seki N.

Intern Med. 2019 Nov 22. doi: 10.2169/internalmedicine.3157-19. [Epub ahead of print]

10.

RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.

Toda H, Seki N, Kurozumi S, Shinden Y, Yamada Y, Nohata N, Moriya S, Idichi T, Maemura K, Fujii T, Horiguchi J, Kijima Y, Natsugoe S.

Mol Oncol. 2020 Feb;14(2):426-446. doi: 10.1002/1878-0261.12602. Epub 2019 Dec 29.

11.

The combined effect of light-illuminating direction and enamel rod orientation on color adjustment at the enamel borders of composite restorations.

Hatayama T, Kano Y, Aida A, Chiba A, Sato K, Seki N, Hosaka K, Foxton RM, Tagami J, Nakajima M.

Clin Oral Investig. 2019 Oct 24. doi: 10.1007/s00784-019-03085-7. [Epub ahead of print]

PMID:
31650317
12.

Involvement of Dual Strands of miR-143 (miR-143-5p and miR-143-3p) and Their Target Oncogenes in the Molecular Pathogenesis of Lung Adenocarcinoma.

Sanada H, Seki N, Mizuno K, Misono S, Uchida A, Yamada Y, Moriya S, Kikkawa N, Machida K, Kumamoto T, Suetsugu T, Inoue H.

Int J Mol Sci. 2019 Sep 11;20(18). pii: E4482. doi: 10.3390/ijms20184482.

13.

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017.

Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, Soejima K, Nogami N, Nagase S, Nishikawa M, Minato K, Takiguchi Y, Seki N, Yamada K, Seto T, Okamoto H.

Mol Clin Oncol. 2019 Oct;11(4):349-353. doi: 10.3892/mco.2019.1903. Epub 2019 Jul 23.

14.

Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis.

Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, Takeuchi T.

Rheumatology (Oxford). 2020 Mar 1;59(3):545-553. doi: 10.1093/rheumatology/kez327.

PMID:
31377799
15.

Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Anticancer Res. 2019 Aug;39(8):4411-4414. doi: 10.21873/anticanres.13612.

PMID:
31366538
16.

Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target.

Yamada Y, Kato M, Arai T, Sanada H, Uchida A, Misono S, Sakamoto S, Komiya A, Ichikawa T, Seki N.

Mol Oncol. 2019 Sep;13(9):1898-1912. doi: 10.1002/1878-0261.12532. Epub 2019 Jun 27.

17.

Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial.

Sakai Y, Seki N, Hamano K, Ochi H, Abe F, Masuda K, Iino H.

Benef Microbes. 2019 May 27:1-12. doi: 10.3920/BM2018.0174. [Epub ahead of print]

PMID:
31131617
18.

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Cancer Chemother Pharmacol. 2019 Sep;84(3):561-566. doi: 10.1007/s00280-019-03874-7. Epub 2019 May 21.

PMID:
31115605
19.

A study of the prebiotic effect of lactulose at low dosages in healthy Japanese women.

Sakai Y, Seki N, Hamano H, Ochi H, Abe F, Shimizu F, Masuda K, Iino H.

Biosci Microbiota Food Health. 2019;38(2):69-72. doi: 10.12938/bmfh.18-013. Epub 2018 Dec 29.

20.

Rare Case of Synchronous Cystic Duct Metastasis from Renal Cell Carcinoma.

Ueda J, Makino H, Yokoyama T, Maruyama H, Hirakata A, Takata H, Seki N, Kikuchi Y, Yoshioka M, Irie T, Yoshida H.

J Nippon Med Sch. 2019 Sep 3;86(4):242-247. doi: 10.1272/jnms.JNMS.2018_86-405. Epub 2019 Apr 26.

21.

Molecular Pathogenesis of Gene Regulation by the miR-150 Duplex: miR-150-3p Regulates TNS4 in Lung Adenocarcinoma.

Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Sanada H, Moriya S, Kikkawa N, Kumamoto T, Suetsugu T, Inoue H.

Cancers (Basel). 2019 Apr 30;11(5). pii: E601. doi: 10.3390/cancers11050601.

22.

Role of pre-miR-532 (miR-532-5p and miR-532-3p) in regulation of gene expression and molecular pathogenesis in renal cell carcinoma.

Yamada Y, Arai T, Kato M, Kojima S, Sakamoto S, Komiya A, Naya Y, Ichikawa T, Seki N.

Am J Clin Exp Urol. 2019 Feb 18;7(1):11-30. eCollection 2019.

23.

Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation.

Khalid M, Idichi T, Seki N, Wada M, Yamada Y, Fukuhisa H, Toda H, Kita Y, Kawasaki Y, Tanoue K, Kurahara H, Mataki Y, Maemura K, Natsugoe S.

Cancers (Basel). 2019 Mar 7;11(3). pii: E327. doi: 10.3390/cancers11030327.

24.

Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.

Fukuhisa H, Seki N, Idichi T, Kurahara H, Yamada Y, Toda H, Kita Y, Kawasaki Y, Tanoue K, Mataki Y, Maemura K, Natsugoe S.

J Hum Genet. 2019 Jun;64(6):521-534. doi: 10.1038/s10038-019-0584-6. Epub 2019 Mar 11.

PMID:
30858505
25.

Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.

Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Int J Urol. 2019 Apr;26(4):506-520. doi: 10.1111/iju.13911. Epub 2019 Feb 28.

PMID:
30818424
26.

Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Med Oncol. 2019 Feb 28;36(4):32. doi: 10.1007/s12032-019-1257-1.

PMID:
30815799
27.

Regulation of KIF2A by Antitumor miR-451a Inhibits Cancer Cell Aggressiveness Features in Lung Squamous Cell Carcinoma.

Uchida A, Seki N, Mizuno K, Yamada Y, Misono S, Sanada H, Kikkawa N, Kumamoto T, Suetsugu T, Inoue H.

Cancers (Basel). 2019 Feb 22;11(2). pii: E258. doi: 10.3390/cancers11020258.

28.

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.

Seki N, Natsume M, Ochiai R, Haruyama T, Ishihara M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, Watanabe K.

Case Rep Oncol. 2019 Jan 21;12(1):91-97. doi: 10.1159/000493088. eCollection 2019 Jan-Apr.

29.

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.

Seki N, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, Watanabe K.

Case Rep Oncol. 2019 Jan 21;12(1):84-90. doi: 10.1159/000493256. eCollection 2019 Jan-Apr.

30.

Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis.

Ota S, Fujigaki Y, Tamura Y, Kojima K, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Seki N.

Case Rep Oncol. 2019 Jan 11;12(1):53-58. doi: 10.1159/000493851. eCollection 2019 Jan-Apr.

31.

Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review.

Ota S, Sakamoto T, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Sasajima Y, Mizota A, Seki N.

Case Rep Oncol. 2019 Jan 11;12(1):47-52. doi: 10.1159/000493850. eCollection 2019 Jan-Apr.

32.

[Development of a New Resilience Scale for Parents of Children with Profound Intellectual and Multiple Disabilities].

Tanaka M, Hisata M, Miyasaka M, Kurata K, Takizawa K, Nishikata M, Tohyama J, Seki N.

Nihon Eiseigaku Zasshi. 2019;74(0). doi: 10.1265/jjh.18025. Japanese.

33.

Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold.

Kotoku M, Maeba T, Fujioka S, Yokota M, Seki N, Ito K, Suwa Y, Ikenogami T, Hirata K, Hase Y, Katsuda Y, Miyagawa N, Arita K, Asahina K, Noguchi M, Nomura A, Doi S, Adachi T, Crowe P, Tao H, Thacher S, Hashimoto H, Suzuki T, Shiozaki M.

J Med Chem. 2019 Mar 14;62(5):2837-2842. doi: 10.1021/acs.jmedchem.8b01567. Epub 2019 Mar 1.

PMID:
30776227
34.

Benefits of a Nationwide Palliative Care Education Program on Lung Cancer Physicians.

Inoue A, Yamaguchi T, Tanaka K, Sakashita A, Aoe K, Seki N, Hagiwara K.

Intern Med. 2019 May 15;58(10):1399-1403. doi: 10.2169/internalmedicine.0872-18. Epub 2019 Feb 1.

35.

Effect of preoperative pregabalin in video-assisted thoracoscopic surgery.

Matsutani N, Seki N.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4028-S4030. doi: 10.21037/jtd.2018.09.82. No abstract available.

36.

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial).

Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, Goto K, Matsui R, Seki N, Shimada T, Ikeda S, Ikegami N, Hama T, Yamamoto N, Sasaki T.

J Pharm Health Care Sci. 2018 Dec 10;4:31. doi: 10.1186/s40780-018-0128-9. eCollection 2018.

37.

Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).

Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.

Int J Urol. 2019 Mar;26(3):342-352. doi: 10.1111/iju.13868. Epub 2018 Dec 13.

PMID:
30548692
38.

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

Okuma Y, Morikawa K, Tanaka H, Yokoyama T, Itani H, Horiuchi K, Nakagawa H, Takahashi N, Bessho A, Soejima K, Kishi K, Togashi A, Kanai Y, Ueda K, Horimoto K, Matsutani N, Seki N.

Thorac Cancer. 2019 Feb;10(2):395-400. doi: 10.1111/1759-7714.12923. Epub 2018 Dec 8.

39.

Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR‑145‑3p on gene regulation.

Shimonosono M, Idichi T, Seki N, Yamada Y, Arai T, Arigami T, Sasaki K, Omoto I, Uchikado Y, Kita Y, Kurahara H, Maemura K, Natsugoe S.

Int J Oncol. 2019 Feb;54(2):673-688. doi: 10.3892/ijo.2018.4657. Epub 2018 Dec 6.

PMID:
30535463
40.

Yeast Mpo1 Is a Novel Dioxygenase That Catalyzes the α-Oxidation of a 2-Hydroxy Fatty Acid in an Fe2+-Dependent Manner.

Seki N, Mori K, Kitamura T, Miyamoto M, Kihara A.

Mol Cell Biol. 2019 Feb 15;39(5). pii: e00428-18. doi: 10.1128/MCB.00428-18. Print 2019 Mar 1.

41.

Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.

Arai T, Kojima S, Yamada Y, Sugawara S, Kato M, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Mol Oncol. 2019 Feb;13(2):322-337. doi: 10.1002/1878-0261.12405. Epub 2018 Dec 21.

42.

Relationship Between Sarcopenia and Both Physical Activity and Lifestyle in Patients With Chronic Liver Disease.

Ohashi K, Ishikawa T, Hoshi A, Suzuki M, Mitobe Y, Yamada E, Abeywickrama HM, Seki N, Koyama C, Aoki H, Koyama Y.

J Clin Med Res. 2018 Dec;10(12):920-927. doi: 10.14740/jocmr3640. Epub 2018 Oct 30.

43.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K.

Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13.

44.

Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.

Uchida A, Seki N, Mizuno K, Misono S, Yamada Y, Kikkawa N, Sanada H, Kumamoto T, Suetsugu T, Inoue H.

Cancer Sci. 2019 Jan;110(1):420-432. doi: 10.1111/cas.13853. Epub 2018 Dec 6.

45.
46.

Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.

Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, Arai T, Maemura K, Fujii T, Horiguchi J, Natsugoe S, Seki N.

J Hum Genet. 2018 Dec;63(12):1197-1210. doi: 10.1038/s10038-018-0510-3. Epub 2018 Sep 18.

PMID:
30228364
47.

Molecular pathogenesis of renal cell carcinoma: Impact of the anti-tumor miR-29 family on gene regulation.

Yamada Y, Sugawara S, Arai T, Kojima S, Kato M, Okato A, Yamazaki K, Naya Y, Ichikawa T, Seki N.

Int J Urol. 2018 Nov;25(11):953-965. doi: 10.1111/iju.13783. Epub 2018 Aug 28.

48.

Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.

Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, Hashimoto H, Hama T, Yamanaka T, Yamamoto N, Itoh K.

Support Care Cancer. 2019 Mar;27(3):1139-1147. doi: 10.1007/s00520-018-4403-y. Epub 2018 Aug 10.

PMID:
30094732
49.

Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis.

Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Arai T, Kumamoto T, Sanada H, Suetsugu T, Inoue H.

J Hum Genet. 2018 Oct;63(10):1015-1028. doi: 10.1038/s10038-018-0497-9. Epub 2018 Aug 6.

PMID:
30082847
50.

Postoperative empyema following lung cancer surgery.

Matsutani N, Yoshiya K, Chida M, Sakaguchi H, Kikkawa T, Fukuda H, Takahashi N, Sawabata N, Horio H, Seki N, Kawamura M.

Oncotarget. 2018 Jul 3;9(51):29810-29819. doi: 10.18632/oncotarget.25629. eCollection 2018 Jul 3.

Supplemental Content

Support Center